Phase II Trial of Weekly Single-Agent Paclitaxel in Platinum/Paclitaxel-Refractory Ovarian Cancer

Abstract

Weekly paclitaxel (80 mg/m(2)) is generally well tolerated and is an active second-line regimen against ovarian cancer that has demonstrated resistance to platinum/paclitaxel delivered on an every-3-week schedule.

Treatment Outcomes of Paclitaxel for Refractory or Recurrent Epithelial Ovarian Cancer Patients in Thailand

“…The median TTP and OS in our platinum-resistant patients were only 3 months and 9 months respectively. These were slightly lower than 4-6 months for TTP and 8-14 months for OS found in other studies which used either weekly (Thirapakawong et al, 2001;Markman et al, 2002;Ghamande et al, 2003) and were comparable to the corresponding figures of 4 months and 9 months from the studies which used the tri-weekly schedule (Trimble et al, 1993;Thigpen et al, 1994).…”

“…We could demonstrate the response of 12.5% in eight evaluable patients of this group. Previous studies showed 16-62% response rate of platinum-resistant disease having paclitaxel (McGuire et al, 1989;Trimble et al, 1993;Thigpen et al, 1994;Thirapakawong et al, 2001;Markman et al, 2002;Ghamande et al, 2003;Kita et al, 2004;Linch et al, 2008). The difference of treatment outcome may be due to the limited number of patients in this particular group of patient.…”

“…Salvage therapy in these settings is non-platinum and non-taxane drug. The responses of refractory or platinumresistant EOC to salvage chemotherapy are generally low and range from 10-20% (Lund et al, 1994;Rose et al, 1998;Gordon et al, 2001;Markman et al, 2002). Although the combined chemotherapy can yield higher responses, a survival improvement cannot be demonstrated (Bookman et al, 2009).…”

Target Therapy in Platinum-Refractory/Resistant Ovarian Cancer: From Preclinical Findings to Current Clinical Practice

“…Paclitaxel, as single agent, represents to date, a good clinical option in term of RR and survival, in particular if we consider weekly schedule [38,39]. Furthermore, the albumin-bound formulation of paclitaxel, nab-paclitaxel too, has been investigated in this setting showing similar RR (23%) and a median PFS of 4.7 months with a good tolerability [40].…”

The merits of vascular targeting for gynecologic malignancies

“…Low-dose cyclophosphamide administered every 6 days had better therapeutic effects than higher doses given every 21 days [53]. Similarly, in clinical trials, weekly taxane chemotherapy has been shown to result in a high rate of objective responses even in individuals with chemotherapy-resistant ovarian cancers [54]. Certain cytotoxic agents, such as vinblastine, cyclophosphamide, and taxanes, have anti-angiogenic properties when administered at 10% to 20% of the MTD in combination with an anti-VEGFR-2 antibody [55].…”